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Why are the studies on these newer agents
important? 
Atrial fibrillation is associated with an increased risk of
stroke (mean= 4.5% per year) and hence necessitates
starting the patients on lifelong oral anticoagulants.
Vitamin K Antagonists, like Warfarin, have been the
mainstay of treatment, but remain grossly underused
because of increased bleeding risk, variability in results
and the need for therapeutic monitoring. The advent of
newer agents like Dabigatran, direct factor IIa (thrombin)
inhibitor and Apixaban and Rivaroxaban, Factor Xa
inhibitors may make this a little easier. These fast acting,
short lived, fixed dosed (unmonitored) agents exhibit
limited drug and food interactions and provide consistent
and predictable anticoagulation.
The Randomised Evaluation of Long-Term
Anticoagulation Therapy (RE-LY) trial evaluated the
efficacy and safety of two doses of Dabigatran relative to
Warfarin in patients with atrial fibrillation. The
Rivaroxaban versus Warfarin in Nonvalvular Atrial
Fibrillation (ROCKET AF) trial compared the outcomes of
Rivaroxaban (20 mg /day) and dose adjusted Warfarin.
Apixaban (2.5 mg BID) was also compared with aspirin
(81-324 mg QD) for stroke prevention in AF Apixaban
Versus Acetylsalicylic Acid to Prevent Strokes
(AVERROES) trial. 
This review highlights the main findings in these three
trials and presents a brief comparison of the efficacy of
Warfarin against Dabigatran, Apixaban and Rivaroxaban. 
Who were the study participants?
RE-LYenrolled and followed 18,113 elderly patients (mean
age: 71.6 ± 8.7 years) from 44 countries in the 2-year
largest ever randomized controlled trial of antithrombotic
therapy. Subjects had a mean CHADS2 2.1 ± 1.1 and apart
from atrial fibrillation had one other stroke predisposing
risk factor : (previous stroke or TIA, left ventricular ejection
fraction < 40%, New York Heart Association heart failure
classification of II or higher, age > 75 years, or age 65-74
years plus diabetes mellitus, hypertension, or coronary
artery disease). History of stroke within 14 days or a severe
one in past 6 months, increased bleeding risk, active liver
diseases, creatinine clearance < 30mL/min were some of
the exclusion criteria. 
The ROCKET AF trial enrolled 14,264 patients (mean
CHADS2>3.5) with non valvular atrial fibrillation and 55%
of them were positive for a history of stroke, TIA or
systemic embolism at the start of the study (median time
707 days). 
The AVERROES trial recruited 5, 599 subjects (mean age 70
years) non valvular atrial fibrillation patients in whom
Vitamin K antagonists were contraindicated and they had
a mean CHADS2 of 2. 86% did not have a previous stroke
or TIA.
What was the intervention?
In RE-LY trial, out of 18,113study participants 6,022were
randomly assigned to either receive adjusted-dose
Warfarin, with INR target 2.0 to 3.0, monitored monthly.
6,015 subjects were administered Dabigatran 110 mg BID
and 6,076 received Dabigatran 150 mg BID. The
categorization employed double blinding.
In ROCKET AF trial, 14,264 patients with non valvular atrial
fibrillation were either administered Rivaroxaban (20
mg/dL) or dose-adjusted warfarin (target INR 2.0-3.0). 
In the AVERROES trial, subjects were randomly assigned to
receive 5mg Apixaban BID or a lower dose 2.5 mg BID if
the patient had age > 80 years, weight < 60 kg or serum
creatinine > 1.5 mg/dL. Doses of Aspirin administered
were 81 mg (64%), 162 mg (27%), 243 mg (2%) or 324 mg
(7%). Study participants were noted for occurrence of
ischaemic or haemorrhagic events and systemic
embolism. Study subjects had a mean CHADS2 ? 2 with 14
% positive for a history of prior stroke.
What were the findings?
Study participants were noted for primary end point i.e.
ischaemic/haemorrhagic stroke and systemic embolism.
Dabigatran, 150 mg BID and 110 mg BID, exhibited lesser
incidence of stroke and systemic embolism (1.11% /year
and 1.53% /year) compared to warfarin (1.69%/year). Net
clinical benefit showed higher RR 7.09% per year for
Warfarin and Dabigatran 110 mg compared to 6.91% per
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yearfor Dabigatran 150 mg. Mortality with Dabigatran 150
mg BID (3.64% year) was lowest overall when compared
to warfarin (4.13% per year; RR, 0.88; 95% CI,0.80-1.03)
and Dabigatran 110 mg BID (3.75%; RR,0.91; 95% CI, 0.80-
1.03). However, major bleeding was lowest (2.71 % per
year) with Dabigatran 110mg BID compared to Warfarin
(3.36 % per year) and Dabigatran 150 (3.11 % per year). 
The ROCKET AF trial showed that 14.9% of patients per
year in the Rivaroxaban group and 14.5% in thewarfarin
groupwere complicated with non-major and major
clinical bleeds. Rivaroxaban administration was also
associated with net benefiti.e. an overall primary end
point incidence of 2.5 % compared to Warfarin (3.61 %) in
subjects with history of prior stroke, TIA or systemic
embolism. 
AVERROES trial attested to the superiority of Apixaban
over Aspirin therapy with incidence of stroke or systemic
embolism 1.67 % and 3.7 % per year. Net clinical benefit of
Apixaban was 5.3% per year and that of Aspirin was 7.2%
per year. In patients who had previously taken Vitamin K
antagonist, Apixaban was more effective in preventing
stroke or systemic embolism, the incidence being 1.4 % as
opposed to 4.2 % per year for Aspirin. 
What were the conclusions? 
These agents were comparable in efficacy overall and
better in safety profile in patients without renal failure
compared to warfarin, albeit at high cost.Based on the
trials some newer international recommendations (AHA
guidelines) emerged and are hence noteworthy. Warfarin
(1A), Dabigatran (1B), Apixaban (1B) and Rivaroxaban (IIa
B) were all indicated for stroke prevention in patients with
non valvular atrial fibrillation. 
How does this affect clinical practice in
Pakistan?
These agents are certainly useful in selected populations.
It must be remembered that missing a dose equates with
being non anticoagulated due to the shorter half-life of
these agents. The safety of combining Dabigatran,
Rivaroxaban, or Apixaban with an antiplatelet agent has
not been established. Reversal also is of concern in
bleeding scenarios. Use of Factor VII, cryoprecipitate or
emergency dialysis has been proposed. Cost will be a
significant barrier in resource poor areas; although studies
may reveal that they may be eventually cost effective due
to less money spent on tests, anticoagulation clinics
avoiding strokes and bleeds. These studies must be
performed locally before these medicines can be widely
recommended regionally. 
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